PMID- 36367094
OWN - NLM
STAT- MEDLINE
DCOM- 20230626
LR  - 20230626
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 57
IP  - 7
DP  - 2023 Jul
TI  - Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the 
      Literature and Implications for Clinical Practice.
PG  - 822-836
LID - 10.1177/10600280221134127 [doi]
AB  - OBJECTIVE: The objective of this article was to review pharmacology, efficacy, 
      safety, and place in therapy of tirzepatide, a dual glucose-dependent 
      insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor 
      agonist. DATA SOURCES: PubMed/MEDLINE and ClinicalTrials.gov were searched 
      through September 7, 2022, using the keyword "tirzepatide." STUDY SELECTION AND 
      DATA EXTRACTION: Clinical trials with available results were included. DATA 
      SYNTHESIS: Seven published phase 3, multicenter, randomized, parallel-group 
      trials investigated efficacy and safety of tirzepatide versus placebo, 
      semaglutide, insulin degludec, and insulin glargine for type 2 diabetes mellitus 
      (T2DM) treatment. Studies included adults with uncontrolled T2DM and body mass 
      index above 23 or 25 kg/m(2). Hemoglobin A1c reduction from baseline was greater 
      with tirzepatide across all studies with absolute reductions up to 3.02% and 
      relative reductions ranging 0.44% (vs semaglutide) to 2.11% (vs placebo). Weight 
      loss was significant. Incidence of gastrointestinal adverse effects (AE) was 
      similar to semaglutide, and major cardiovascular events was similar to insulin 
      glargine. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: Studies demonstrated 
      greater A1c lowering and weight reduction versus placebo and active comparators 
      with AE similar to semaglutide, suggesting tirzepatide will be a valuable 
      addition to the growing list of antidiabetic medications. Although tirzepatide's 
      effects on major cardiovascular events was not increased when compared with 
      insulin glargine, further evidence is needed to assess long-term implications on 
      cardiovascular outcomes compared with agents with proven cardiovascular benefits. 
      CONCLUSIONS: Tirzepatide has the potential to significantly impact the clinical 
      management of T2DM, and results of ongoing clinical trials will help to fully 
      determine its place in therapy.
FAU - Bradley, Courtney L
AU  - Bradley CL
AD  - Department of Clinical Sciences, Fred Wilson School of Pharmacy, High Point 
      University, High Point, NC, USA.
FAU - McMillin, Sara M
AU  - McMillin SM
AD  - Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High 
      Point University, High Point, NC, USA.
FAU - Hwang, Andrew Y
AU  - Hwang AY
AUID- ORCID: 0000-0002-9766-7711
AD  - Department of Clinical Sciences, Fred Wilson School of Pharmacy, High Point 
      University, High Point, NC, USA.
FAU - Sherrill, Christina H
AU  - Sherrill CH
AUID- ORCID: 0000-0003-1054-0644
AD  - Department of Clinical Sciences, Fred Wilson School of Pharmacy, High Point 
      University, High Point, NC, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221111
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - OYN3CCI6QE (tirzepatide)
RN  - 0 (Glycated Hemoglobin)
RN  - 0 (Hypoglycemic Agents)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Insulin Glargine/therapeutic use
MH  - Glycated Hemoglobin
MH  - Hypoglycemic Agents/adverse effects
MH  - Gastric Inhibitory Polypeptide/therapeutic use
MH  - Weight Loss
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Multicenter Studies as Topic
OTO - NOTNLM
OT  - diabetes
OT  - glucagon-like peptide-1
OT  - glucose-dependent insulinotropic polypeptide
OT  - obesity
OT  - tirzepatide
OT  - twincretin
OT  - type 2 diabetes
OT  - weight loss
EDAT- 2022/11/12 06:00
MHDA- 2023/06/26 06:41
CRDT- 2022/11/11 05:02
PHST- 2023/06/26 06:41 [medline]
PHST- 2022/11/12 06:00 [pubmed]
PHST- 2022/11/11 05:02 [entrez]
AID - 10.1177/10600280221134127 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2023 Jul;57(7):822-836. doi: 10.1177/10600280221134127. Epub 
      2022 Nov 11.